Yesterday, June 7, 2016, 85 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $15.84 to $78,975,000.00.

Highlighted Stocks Traded by Insiders:

Ophthotech (OPHT) - FREE Research Report

Bolte Axel, who is Director at Ophthotech, bought 3,500 shares at $56.97 on June 7, 2016. Following this transaction, the Director owned 6,000 shares meaning that the stake was boosted by 140% with the 3,500-share transaction.

The shares most recently traded at $57.77, up $0.80, or 1.38% since the insider transaction. Historical insider transactions for Ophthotech go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 1.3 million
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 1.4 million
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 1.4 million

The average volume for Ophthotech has been 487,900 shares per day over the past 30 days. Ophthotech has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are down 27.23% year-to-date as of the close of trading on Tuesday.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Currently, there are 9 analysts who rate Ophthotech a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPHT - FREE

TheStreet Quant Ratings

rates Ophthotech as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full

Ophthotech Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Maximus (MMS) - FREE Research Report

Webb Wellington E, who is Director at Maximus, sold 560 shares at $56.95 on June 7, 2016. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 560-share transaction.

The shares most recently traded at $57.78, up $0.83, or 1.43% since the insider transaction. Historical insider transactions for Maximus go as follows:

  • 4-Week # shares bought: 14,375
  • 4-Week # shares sold: 34,250
  • 12-Week # shares bought: 14,375
  • 12-Week # shares sold: 34,250
  • 24-Week # shares bought: 14,375
  • 24-Week # shares sold: 35,250

The average volume for Maximus has been 376,400 shares per day over the past 30 days. Maximus has a market cap of $3.7 billion and is part of the services sector and diversified services industry. Shares are up 1.55% year-to-date as of the close of trading on Tuesday.

MAXIMUS, Inc. provides business process services (BPS) to government health and human services in the United States, the United Kingdom, Australia, Canada, Saudi Arabia, and New Zealand. The stock currently has a dividend yield of 0.32%. The company has a P/E ratio of 24.8. Currently, there are 5 analysts who rate Maximus a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMS - FREE

TheStreet Quant Ratings

rates Maximus as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Maximus Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mellanox Technologies (MLNX) - FREE Research Report

Riordan Thomas, who is Director at Mellanox Technologies, sold 1,000 shares at $47.89 on June 7, 2016. Following this transaction, the Director owned 57,544 shares meaning that the stake was reduced by 1.71% with the 1,000-share transaction.

Sultzbaugh Marc, who is Sr. VP World Wide Sales at Mellanox Technologies, sold 5,000 shares at $49.05 on June 7, 2016. Following this transaction, the Sr. VP World Wide Sales owned 73,937 shares meaning that the stake was reduced by 6.33% with the 5,000-share transaction.

The shares most recently traded at $50.36, up $1.31, or 2.6% since the insider transaction. Historical insider transactions for Mellanox Technologies go as follows:

  • 4-Week # shares bought: 57,739
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 57,739
  • 12-Week # shares sold: 32,063
  • 24-Week # shares bought: 57,739
  • 24-Week # shares sold: 66,770

The average volume for Mellanox Technologies has been 678,600 shares per day over the past 30 days. Mellanox Technologies has a market cap of $2.3 billion and is part of the technology sector and electronics industry. Shares are up 19.32% year-to-date as of the close of trading on Tuesday.

Mellanox Technologies, Ltd., a fabless semiconductor company, designs, manufactures, and sells interconnect products and solutions. The company has a P/E ratio of 31.3. Currently, there are 8 analysts who rate Mellanox Technologies a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MLNX - FREE

TheStreet Quant Ratings

rates Mellanox Technologies as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full

Mellanox Technologies Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.